Result
€76,696 ▲ 201%
The result rose in 2025 from €25,500 to €76,696.
ENDOGYN
Overview
Lifetime
2 annual accounts with figures on one time axispeak €106,241 (2025)
€106,241▲ 221%
peak €76,696 (2025)
€76,696▲ 201%
peak €102,296 (2025)
€102,296▲ 300%
€33,046▲ 72.9%
Board1 name since 2024
1 director
Documentsfilings and deeds
17-06-202644 days before the deadline
2025micro format
Gross margin from €33,114 to €106,241Result from €25,500 to €76,696Equity from €25,600 to €102,296Debts from €19,115 to €33,046Cash from €10,196 to €62,718
Key points
from the 2025 annual accountsInvestments
€10,398 1.7 × depreciation
Green is investment, beige is depreciation.
Liquidity
3.69 was 1.85 in 2024
Short-term debts rose from €18,962 to €32,893.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 39,326 companies had the same profile as ENDOGYN has now. Each dot stands for 99 companies, two years later.
95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,326 companies, not a prediction for ENDOGYN. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered office moved from Ixelles to Wépion
New registered office: 140 Tienne aux Clochers à 5100 Wépion · Previous registered office: Avenue du Pesage 61 bte 25-1050 Ixelles · General meeting of 22-11-2024 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1011001306
Incorporation
Founding capital of €100, 100 shares · Founder: (fondateur et souscripteur) · Appointment: (director) · published on 03-07-2024 · Gazette deed
First establishment
Varenslaan 34, Overijse
Official details
Source: KBO- Status
- Active since 01-07-2024Normal situation
- Activity
- “En assurant la gestion d’un centre médical ou d’un cabinet médical, en ce compris…” (deed in French)From the articles, 7 activitiesNo NACE code in the KBO yet
- Establishment unit
- 2.373.938.3093090 Overijse, since 01-07-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 28-11-2024
Annual accounts 2025
- €106,241▲ 221%
- ≈ €270,000estimated
- €76,696▲ 201%
- €102,296▲ 300%
- €135,342▲ 203%
- Filing
- Filed on 17-06-2026, 44 days before the end of the filing period
Insights on ENDOGYN
ENDOGYN has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €102,296 and a net result of €76,696.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
micro format, filed on 17-06-2026, 44 days before the deadline€106,241
▲ 221%
€99,226
▲ 206%
€76,696
▲ 201%
€88,515
▲ 450%
75.6%
▲ 18.3 percentage points
3.69
▲ 1.84
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €270,000. Estimated: probably between €180,000 and €410,000.
Balance sheet
balance sheet total €135,342 on 31-12-2025What the company ownsHow it is paid for
in euro
in euro
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 |
|---|---|---|---|
| Balance sheet: assets | |||
20/58 |
135,342 | 44,716 | |
21/28 |
13,935 | 9,658 | |
22/27 |
13,935 | 9,658 | |
24 |
7,333 | 9,658 | |
26 |
6,602 | - | |
29/58 |
121,408 | 35,058 | |
54/58 |
62,718 | 10,196 | |
490/1 |
58,689 | 24,862 | |
| Balance sheet: equity and liabilities | |||
10/49 |
135,342 | 44,716 | |
10/15 |
102,296 | 25,600 | |
10/11 |
100 | 100 | |
14 |
102,196 | 25,500 | |
17/49 |
33,046 | 19,115 | |
42/48 |
32,893 | 18,962 | |
44 |
101 | 628 | |
440/4 |
101 | 628 | |
45 |
24,858 | 6,693 | |
450/3 |
22,325 | 6,693 | |
454/9 |
2,533 | - | |
47/48 |
7,934 | 11,641 | |
492/3 |
153 | 153 | |
| Income statement | |||
9900 |
106,241 | 33,114 | |
630 |
6,121 | 342 | |
640/8 |
893 | 387 | |
9901 |
99,226 | 32,384 | |
65/66B |
206 | 191 | |
65 |
206 | 191 | |
9903 |
99,021 | 32,193 | |
67/77 |
22,325 | 6,693 | |
9904 |
76,696 | 25,500 | |
9905 |
76,696 | 25,500 | |
| Appropriation of the result | |||
9906 |
102,196 | 25,500 | |
14P |
25,500 | - | |
| Document | |||
The notes to these accounts have 5 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 17-06-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankKey figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 |
|---|---|---|---|
| 105,348 | 32,727 | ||
| 82,817 | 25,843 | ||
| 10,398 | 10,000 | ||
| 52,522 | - | ||
| 88,515 | 16,096 | ||
| 75.6% | 57.3% | ||
| 3.69 | 1.85 | ||
| 0.32 | 0.75 | ||
| 75.0% | 99.6% | ||
| 56.7% | 57.0% | ||
| over 100 | over 100 |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Investments
fixed assets acquired| Item | 2025 | 2024 |
|---|---|---|
| Tangible fixed assets | €10,398 | €10,000 |
| €6,121 | €342 |
Source: notes to the 2024 to 2025 annual accounts (statement of fixed assets)
Insights on ENDOGYN
The operating result for 2025 is nearly 3.1 times that of 2024.
Debt's share of the balance-sheet total falls from 42.7% to 24.4%. Equity and debt are higher.
Board & ownership
Board
1 director, since incorporationDirector (not named in the articles)
since 01-07-2024
term without a fixed end
listed in the 2025 annual accounts, filed on 17-06-2026
Mandates through the years
1 name, the dashed line is todayDirector (not named in the articles)
Board
Mandates as a list
-
- Director (not named in the articles), from 01-07-2024 to date
Control
Founder
This company
ENDOGYN
Equity €102,296
Profit €76,696 in 2025
Capital
- Contribution
- €100
- Shares
- 100
- Contribution per share
- €1
- Equity per share
- €1,023 in 2025
- Source
- deed of 03-07-2024
Articles of association
deed of 03-07-2024 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Un ou plusieurs actionnaires-médecins, assemblée générale détermine nombre durée pouvoirs en pluralité, défaut durée mandat sans limitation”“Fixe ou proportionnelle, assemblée générale”
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Second Tuesday of June at 16:00
- Statutory auditorA statutory auditor is a registered auditor who checks the annual accounts. Small companies need not have one. According to the deed, the legal criteria do not require one here.
- No statutory auditor
Shareholders
At incorporation
deed of 03-07-2024 ↗
- 100 shares
Network & group
No group
ENDOGYN has no parent and no holdings in its annual accounts. is the only director. ENDOGYN shares no director with another company.
The LEI register names no parent.
Timeline
Timeline
7 events since 2024Filings
Financial
Establishments
Address
202420252026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBmicro format · 44 days before the deadline
2025
Equity above €100,000 equity €102,296 ▲300% With a profit in every financial year since 2024, equity grows to €102,296.
Annual accounts 2024 filed NBBmicro format · 41 days before the deadline
2024
Registered office moved from Ixelles to WépionNew registered office: 140 Tienne aux Clochers à 5100 Wépion · Previous registered office: Avenue du Pesage 61 bte 25-1050 Ixelles · General meeting of 22-11-20242 points ▸
- General meeting, 22-11-2024
- Registered-office move, 140 Tienne aux Clochers à 5100 Wépion
Registered in the Peppol Directory Reachable for e-invoices through 0208:1011001306
IncorporationFounding capital of €100, 100 shares · Founder: (fondateur et souscripteur) · Appointment: (director) · published on 03-07-20248 points ▸
- Registered office clause, avenue du Pesage 61/25, 1050 Ixelles
- Board rule, 1
- Director appointment, (director (not named in the articles))
- Permanent representative,
- Founder, (fondateur et souscripteur)
- Founding capital, €100, 100 shares
- holds 100 shares
- 100 shares
- The deed holds 9 more points.
First establishment Varenslaan 34, Overijse
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Identity
- Enterprise number
- 1011.001.306
- VAT number
- BE 1011.001.306
- Peppol ID
- 0208:1011001306
- Other Peppol ID
- 9925:BE1011001306
- LEI code
- 254900I7TV98UAC1CC24 live in the LEI register
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 01-07-2024
- Financial year
- ends on 31 December
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Second Tuesday of June at 16:00deed of 03-07-2024 (in French)
- Peppol
- Reachable since 28-11-2024Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- ENDOGYN in French
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 03-07-2024 (in French)
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Région de Bruxelles-Capitale”deed of 03-07-2024 (in French)
Activities
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “En assurant la gestion d’un centre médical ou d’un cabinet médical, en ce compris l’acquisition, la location et l’entretien du matériel…”deed of 03-07-2024 (in French)
7 activities
- En assurant la gestion d’un centre médical ou d’un cabinet médical, en ce compris l’acquisition, la location et l’entretien du matériel médical et des biens d’équipement, la facturation et la perception d’honoraires médicaux, la mise à disposition de tout ce qui est nécessaire à la pratique de l’art de guérir.
- En permettent la création, la construction, la location, l’acquisition, l’organisation et le fonctionnement d’un cabinet médical ou d’un centre médical de nature à faciliter l’exercice de la profession de cardiologie,
- En assurant la défense des intérêts professionnels, moraux et matériels des médecins travaillant dans le cadre de la société.
- Pour son propre compte, et à titre accessoire, l'acquisition (en pleine-propriété ou en usufruit), la construction, la transformation, l'amélioration, l'aménagement, l'embellissement, l'entretien de biens immeubles, et ce pour autant que son caractère civil soit préservé et qu'elle n'en fasse pas une activité commerciale. De plus de tels investissements ne pourront se réaliser qu'à la majorité des deux tiers minimum ;
- La société se donne également pour objet de favoriser la recherche scientifique en organisant des activités de recyclage et en nouant des contacts avec tous les organismes poursuivant les mêmes buts, en exerçant des activités d’auteur.
- En assurant l’organisation et éventuellement la dispense de cours de médecine, mais aussi la formation tant aux étudiants relevant du secteur de la médecine que du secteur de la psychiatrie
- En assurant la formation de médecins assistants en filière de médecine psychiatrique
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Tienne aux Clochers 140 registered office 5100 Namur | ||
| Varenslaan 34 3090 Overijse 86220 Specialist medical practice | 01-07-2024 | 2.373.938.309 |
1 former office
- Avenue du Pesage 61 bte 25, 1050 Ixelles until 22-11-2024 · deed of 11-12-2024
Buildings and parcels at the addresses
- Ground area
- 6,273 m²
- Buildings
- 313 m²
- Volume, LiDAR
- 1,825 m³
- Tallest building
- 8.4 m
Buildings to scale, each on its own parcel
Parcels
Flanders
1
(50%)
Wallonia
1
(50%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 92135H0190/00K000 | Wallonia | 4,512 m² | 1 · 199 m² | 8.3 m · 2 |
| 23543K0085/00Y020 | Flanders | 1,761 m² | 1 · 115 m² | 7.3 m · 2 |